Sankala Group’s Vaxcyte PCVX Stock Holding History

Sankala Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1K	Hold	186	–	–	0.01%	379
2025 Q4	$11.5K	Buy	+186	New	+$8.32K	0.01%	370

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sankala Group's PCVX Position: Q1 2026 in Review

Sankala Group held its Vaxcyte (PCVX) position steady in Q1 2026 at 186 shares worth $10.1K. The position accounts for 0.01% of the portfolio, ranked #379.

Sankala Group first reported a position in PCVX in Q4 2025 and has held it in 2 quarters since. The position peaked at $11.5K in Q4 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Sankala Group held 186 shares of Vaxcyte worth $10.1K as of Q1 2026.
Sankala Group left its Vaxcyte share count unchanged in Q1 2026.
Vaxcyte made up 0.01% of Sankala Group's portfolio in Q1 2026, its #379 holding.
Sankala Group first reported a position in Vaxcyte in Q4 2025 and has held it in 2 quarters since.
Sankala Group's Vaxcyte position peaked at $11.5K in Q4 2025.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.